Jounce Therapeutics is a clinical stage immunotherapy company discovering and developing novel cancer immunotherapies designed to mobilize the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine has the potential to discover novel biological insights to drive the development of game-changing immunotherapy treatments with highly durable responses, extending and improving patients’ quality of life. Jounce is identifying product candidates from Next-generation T-cell checkpoint modulators and Tumor Microenvironment (TME) modifiers.